This article was originally published in The Rose Sheet
Executive SummaryTotal Care launch in the UK, contributes to brand sales growth of 6.5% to $73.6 mil. in the first half (ended Sept. 30), Boots reports. Flat performance in the U.S. was due to inventory reductions in the trade offsetting rising consumer sales, according to the retailer. Boots Healthcare International sales increased 11.7% in the half to $381.1 mil., while operating profit was up 1.1% to $59.4 mil. Brand investment in the period was up 3% to $121.4 mil., largely due to continued investment behind Clearasil...
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.